Cargando…
Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia
Background and Objectives: BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and elderly patients with chronic lymphocytic leukemia (CLL), but their long-term efficacy and toxicity are still unknown and the costs are considerable. Our previous data showed that Rituximab (Rtx)...
Autores principales: | Pileckyte, Regina, Valceckiene, Vilma, Stoskus, Mindaugas, Matuzeviciene, Reda, Sejoniene, Jurgita, Zvirblis, Tadas, Griskevicius, Laimonas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915691/ https://www.ncbi.nlm.nih.gov/pubmed/31671877 http://dx.doi.org/10.3390/medicina55110719 |
Ejemplares similares
-
Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability
por: Giedraitiene, Natasa, et al.
Publicado: (2015) -
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021) -
Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000–2013
por: Beinortas, Tumas, et al.
Publicado: (2016) -
RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
por: Castro, Januario E., et al.
Publicado: (2009) -
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2019)